Pfizer Inc. is in the biosimilar market for the long game, despite the commercial challenges it has faced with its first biosimilar to launch in the US – Inflectra (infliximab-dyyb). That was the message the company's Essential Health leadership set out during a briefing on the company's biosimilar strategy at Pfizer's New York headquarters April 10.
"The market for biosimilars is alive and it's real and it's here to stay," Essential Health Group President Angela Hwang...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?